February 25, 2025. ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a member of the Eurobiomed ecosystem, has just been awarded €8.7 million under theCall for Proposals i-Demo of the France 2030 plan, operated by Bpifrance. This major funding will support the clinical validation of an innovative biotherapy against generalized infection (sepsis), which affects over 49 million people and causes almost 11 million deaths worldwide every year.
Approved by Eurobiomed's Strategic Project Council in May 2024, this project is fully in line with the cluster's roadmap, which aims to help bring 5 biomedicines to market. Eurobiomed's expertise, in close collaboration with the teams at Bpifrance and the Agence de l'Innovation en Santé, was decisive in putting together this strategic and complex dossier, in terms of both the scientific and medical aspects and the bioproduction aspect, demonstrating its ability to support the most ambitious projects in its region.
In 2024, Eurobiomed, a member of the French health cluster alliance Enosis Santé, secured 71.7 million euros in i-Démo public funding for its members, confirming the region's innovation momentum. Production will be carried out in part by GTP Bioways, a major player in biomanufacturing and the Eurobiomed community, illustrating the strength of the network and the synergies created within the ecosystem between these flagships of the Biothérapie Innovation Occitanie cluster.
" This success demonstrates once again the relevance of our support, particularly in setting up solid financing strategies", emphasizes Emilie Royère, Eurobiomed's Managing Director. " Supporting ABIONYX Pharma's committed team is perfectly in line with our mission to nurture tomorrow's European champions, and confirms our region's position at the cutting edge of healthcare innovation.
" Eurobiomed's support was decisive in obtaining this financing", says Cyrille Tupin, CEO of ABIONYX Pharma. " This exemplary collaboration will accelerate the development of the first specific, targeted solution for sepsis, the third leading cause of death worldwide.
